Thoracic Cancer – NCI-06-C-0014
Dr. David Schrump
Principal Investigator
NCI is currently conducting the following trial for patients with thoracic malignancies. Click on the trial below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact Dr. Schrump and his staff directly.
You may also call the Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937) to inquire about referring a patient to this trial.
Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies
NCI-06-C-0014
- Participants undergo standard tests for evaluating the stage of their disease and for determining their eligibility for participation in an NCI treatment study
- Participants undergo bronchoscopy and bronchoalveolar lavage, standard tumor assessment procedures
- Participants undergo tumor biopsy
- Treatment options are discussed after the patient’s cancer is staged
- Patients who are eligible for a treatment study at NCI are offered participation in the study
- Patients for whom standard surgery, radiation, or chemotherapy is more appropriate may receive treatment at NCI or with their own physician
- Patients who receive treatment at NCI return for follow-up examinations 4 weeks after discharge and then every 2-4 months depending on the nature of their cancer
Why is this trial important?
This protocol is designed to facilitate screening of patients for investigational protocols in the Thoracic Oncology Section, Surgery Branch, NCI, and in doing so, obtain tissue samples to enable evaluation of epigenetic events in primary and metastatic thoracic malignancies, as an extension of ongoing laboratory research in the Thoracic Oncology laboratory.
Back to Top
